• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Redeye: Tagmaster Q3’2024 - Weak market outlook lowers valuation

TAGM BPress release24.10.2024, 09.03

Redeye sees high uncertainty until the underlying market recovers. The current organic sales trend is fragile, to a high degree, dependent on a weak market for infrastructure investments. Due to the uncertain outlook, we cut our estimates for the rest of 2024 and the following years. We recognize that Tagmaster seems to hold its market share, which is a positive when the market turns around. With the significant cut in our estimates and the fact that we do not see a real rebound in the market until H2 2025e, we lower our Base case to SEK 21.6(28) per share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science andTechnology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Tagmaster Q3’2024 - Weak market outlook lowers valuation